[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT07731425":3,"trial-entities:NCT07731425":98,"trial-summary:NCT07731425":102},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":20,"study_type":24,"primary_purpose":14,"phases":25,"enrollment_info":27,"interventions":30,"primary_outcomes":55,"secondary_outcomes":60,"sex":64,"minimum_age":65,"maximum_age":66,"healthy_volunteers":15,"eligibility_criteria":67,"std_ages":73,"locations":76,"central_contacts":92,"overall_officials":95,"references":96,"see_also_links":97},"NCT07731425","714377A","Patients' Expectations About the Survival Benefits of Cancer Drugs Approved Based on Progression-Free Survival","Patients' Expectations About the Survival Benefits of Cancer Drugs Approved Based on Progression-Free Survival: a Randomized Controlled Trial","NOT_YET_RECRUITING","2026-10-01","2026-07","2026-07-28","2026-08-01","London School of Economics and Political Science","OTHER",false,"This study of current or former cancer patients will evaluate whether communicating data on overall survival data in addition to information on progression-free improves the accuracy of cancer patients' expectations about the survival benefits of new cancer drugs","Progression-free survival (PFS) (the time until a tumour grows, spreads, or the patient dies) is among the most common outcomes supporting the approval of new cancer drugs. Likely owing to similar terminology and the use of the word 'survival', patients often confuse PFS with overall survival, which may lead to treatment decisions that are not aligned with patients' individual preferences. Alternative descriptions of PFS that acknowledge the absence of a survival benefit may improve understanding.\n\nThis randomized controlled trial will evaluate whether communicating data on overall survival data in addition to information on progression-free improves the accuracy of cancer patients' expectations about the survival benefits of new cancer drugs, since patients may only understand the distinction between these outcomes when they are presented with data on both. Three alternative descriptions for PFS will be compared, including those used by the FDA, the National Cancer Institute, and a plain-language version that was developed drawing on prior work about communicating PFS. This study will also compare the additive effect of overall survival data for each alternative description of PFS.",[19],"Cancer",[21,22,23],"cancer","prescription drugs","progression-free survival","INTERVENTIONAL",[26],"NA",{"count":28,"type":29},3000,"ESTIMATED",[31,35,39,43,47,51],{"type":14,"name":32,"description":33,"armGroupLabels":34},"FDA explanation for progression-free survival (control)","Progression-free survival",[32],{"type":14,"name":36,"description":37,"armGroupLabels":38},"FDA explanation for progression-free survival with overall survival data","The description, 'progression-free survival', along with data on overall survival.",[36],{"type":14,"name":40,"description":41,"armGroupLabels":42},"NCI explanation for progression-free survival","The description, 'the length of time during and after treatment that a patient lived with the cancer but it did not get worse'.",[40],{"type":14,"name":44,"description":45,"armGroupLabels":46},"NCI explanation for progression-free survival with overall survival data","The description, 'the length of time during and after treatment that a patient lived with the cancer but it did not get worse', along with data on overall survival.",[44],{"type":14,"name":48,"description":49,"armGroupLabels":50},"Plain-language explanation of progression-free survival","The description, 'the length of time until a test showed the cancer grew, spread, or worsened'.",[48],{"type":14,"name":52,"description":53,"armGroupLabels":54},"Plain-language explanation of progression-free survival with overall survival data","The description, 'the length of time until a test showed the cancer grew, spread, or worsened', along with data on overall survival.",[52],[56],{"measure":57,"description":58,"timeFrame":59},"Accuracy of expectations about the survival benefits of a new cancer drug approved based on progression-free survival","Compared to standard treatment, do patients with advanced kidney cancer live longer when treated with Velotrex?\n\n\\- Response options: definitely yes, probably yes, probably no, definitely no","Assessed immediately after the intervention",[61],{"measure":62,"description":63,"timeFrame":59},"Perceptions of drug benefits and risks","How would you describe the benefits of Velotrex?\n\n\\- Very large, large, moderate, small, very small to none\n\nDo you think the benefits of Velotrex outweigh the side effects? - Response options: definitely yes, probably yes, probably no, definitely no\n\nWhich treatment would you recommend to a patient with kidney cancer\n\n\\- Response options: Velotrex, standard treatment","ALL","18 Years",null,{"inclusion":68,"exclusion":71,"raw_text":72},[69,70],"US adults with a current or former cancer diagnosis (excluding nonmelanoma skin cancer)","US adults 18 years of age and older, fluent in English, and residing in the United States.",[],"Inclusion Criteria:\n\n* US adults with a current or former cancer diagnosis (excluding nonmelanoma skin cancer)\n* US adults 18 years of age and older, fluent in English, and residing in the United States.\n\nExclusion Criteria:\n\n* Adults who do not have a former cancer diagnosis or who were diagnosed with nonmelanoma skin cancer; adults who complete the survey in under 150 seconds, and who do not meet the other inclusion criteria.",[74,75],"ADULT","OLDER_ADULT",[77],{"facility":78,"city":79,"state":80,"zip":81,"country":82,"contacts":83,"geoPoint":89},"Harvard Medical School and Harvard Pilgrim Health Care Institute","Boston","Massachusetts","02215","United States",[84],{"name":85,"role":86,"phone":87,"email":88},"Avi Cherla","CONTACT","020 7852 3727","avi_cherla@hphci.harvard.edu",{"lat":90,"lon":91},42.35843,-71.05977,[93],{"name":85,"role":86,"phone":94,"email":88},"020 7955 7975",[],[],[],{"nct_id":4,"conditions":99,"biomarkers":101},[100],"Malignant Neoplasm",[],{"nct_id":4,"found":103,"summary":104,"prompt_version":114},true,{"design":105,"status":106,"heading":107,"summary":108,"follow_up":109,"word_count":110,"commitments":111,"compensation":112,"drugs_mentioned":113},"This is an interventional study planning to enroll 3000 participants. It will compare different ways of explaining cancer drug benefits.","completed","Understanding Cancer Drug Benefits: A Study for Patients","This study aims to understand how different explanations of cancer drug benefits affect patients' expectations. It's looking at how people with a current or past cancer diagnosis (excluding nonmelanoma skin cancer) understand \"progression-free survival\" (PFS), which is the time a patient lives with cancer without it getting worse. You'll be presented with different ways of explaining PFS, including those from the FDA and National Cancer Institute, and a plain-language version. Some explanations will also include information about \"overall survival\" (how long a person lives). The study wants to see if adding overall survival data helps patients better understand the true benefits of new cancer drugs. The goal is to improve how information is shared so patients can make informed decisions. This study is for US adults, 18 or older, who speak English and have had cancer.","Your expectations about survival benefits will be assessed immediately after you receive the information.",136,"Not specified in the trial record.","Not stated in the trial record.",[],"v2"]